April 10, 2008
1 min read
Save

Vitreoretinal Technologies begins enrollment for phase 3 trial of investigational diabetic retinopathy drug

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

IRVINE, Calif. — Vitreoretinal Technologies has begun enrollment in the United States and India for a phase 3 clinical trial evaluating the safety and efficacy of Vitreosolve, an investigational drug for treating patients with diabetic retinopathy, the company announced in a press release.

The study is the first of two pivotal trials required by the U.S. Food and Drug Administration for the submission of a new drug application, according to the press release.

Vitreoretinal Technologies is also developing Neurosolve, a neuronal rescue agent for treating patients with glaucoma and retinitis pigmentosa. Both Vitreosolve (carbamide) and Neurosolve are small molecules that have shown safety and efficacy for systemic use in phase 2 clinical trials, the release said.